
Corbus Pharmaceuticals Holdings, Inc.
93
Recent developments highlight Corbus Pharmaceuticals' advancement in clinical trials and management changes, with significant news on Phase 3 cancer trial initiation and positive obesity study results.
- Corbus Pharmaceuticals launched a Phase 3 cancer trial for CRB-701 and teased additional obesity drug data in November 2026 [N1].
- CRB-913 demonstrated 5% weight loss in a Phase 1b obesity study reported in September 2026 [N2].
- Leonardo Viana Nicacio was appointed Chief Medical Officer in July 2026 [N3].
- The company teased key clinical readouts for cancer and obesity programs in mid-2026 [N4][N6].
- Corbus targets HPV-linked head and neck cancer with CRB-701 studies as of June 2026 [N5].
- Guggenheim initiated coverage with a buy recommendation in April 2026 [N7].
- Wall Street analysts publicly discussed upside potential for Corbus Pharmaceuticals in March 2026 [N8].
Corbus Pharmaceuticals Holdings, Inc. focuses on developing innovative therapies in oncology and obesity. Its pipeline includes CRB-701, an antibody drug conjugate targeting Nectin-4 on cancer cells, and CRB-913, a cannabinoid receptor inverse agonist for obesity treatment. CRB-701 is in Phase 1/2 clinical trials in the U.S. and Europe, with ongoing dose expansion and combination studies. CRB-913 has completed Phase 1a studies demonstrating safety and early efficacy signals and is advancing through Phase 1b trials. The company has deprioritized its CRB-601 program. Corbus relies on third-party manufacturers for drug supply and holds licenses for its key drug candidates. Financially, as of Q3 2026, the company maintains a strong liquidity position with over $30 million in cash and equivalents and a current ratio of 3.4.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies in oncology and obesity. Its lead oncology candidate, CRB-701, is a next-generation antibody drug conjugate targeting Nectin-4, currently in Phase 1/2 trials with FDA fast track designations for cervical and head and neck cancers. CRB-913 is an oral CB1 receptor inverse agonist in clinical development for obesity, showing positive Phase 1a and Phase 1b study results. The company reported a net loss of $37.8 million and held $30.2 million in cash and equivalents as of September 30, 2026, with a strong liquidity position. Recent developments include initiation of a Phase 3 cancer trial and management appointments. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. [S2]
Corbus Pharmaceuticals has advanced clinical-stage candidates with differentiated mechanisms targeting significant unmet needs in oncology and obesity. Positive Phase 1/2 data for CRB-701 and early obesity efficacy signals for CRB-913 demonstrate potential clinical benefits and manageable safety profiles. The company’s licensing agreements and patent portfolio provide intellectual property protection. Recent initiation of a Phase 3 cancer trial and ongoing dose expansion studies represent key milestones. Strong liquidity supports continued development activities. Favorable regulatory designations such as FDA fast track status may facilitate development pathways.
Corbus Pharmaceuticals faces risks typical of clinical-stage biopharmaceutical companies, including clinical trial uncertainties, regulatory hurdles, and reliance on third-party manufacturers. The absence of approved products means ongoing net losses and capital requirements. The deprioritization of CRB-601 indicates pipeline attrition risk. Safety or efficacy issues in trials could delay or halt development. Intellectual property challenges or competition from established therapies may impact commercial prospects. Financial liquidity, while currently adequate, requires careful management to sustain operations through clinical milestones.
Corbus Pharmaceuticals' moat is based on its proprietary drug candidates with novel mechanisms and formulations, supported by exclusive licensing agreements and patent protections extending into the 2040s. Its CRB-701 ADC employs advanced linker technology designed to improve safety and efficacy over existing therapies. The company’s focus on peripherally restricted CB1 inverse agonists for obesity addresses unmet medical needs distinct from current treatments. Intellectual property rights and clinical data from ongoing trials contribute to its competitive positioning. However, as a clinical-stage company without commercial products, its moat depends heavily on successful clinical development and regulatory approvals.
• Clinical Development Risk: The success of Corbus depends on positive clinical trial outcomes for CRB-701 and CRB-913. Negative or inconclusive results could delay or prevent regulatory approval.
• Regulatory Risk: Obtaining regulatory approvals involves complex processes and uncertainties. Delays or denials could materially impact the company’s ability to commercialize its drug candidates.
• Manufacturing and Supply Risk: Corbus relies on third-party manufacturers for drug supply. Disruptions or quality issues could delay clinical trials or commercialization.
• Financial Risk: As a clinical-stage company with net losses, Corbus requires sufficient capital to fund operations. Inadequate liquidity or inability to raise funds could impair development programs.
• Intellectual Property Risk: The company’s competitive position depends on maintaining patent protections and licenses. Challenges to intellectual property rights could affect exclusivity and market potential.
Business trends: Advancement of CRB-701 and CRB-913 clinical programs with ongoing trials and regulatory designations; increasing clinical data disclosures and management appointments.
Execution milestones: Completion of Phase 1b obesity study, initiation of Phase 3 cancer trial, and planned FDA meetings for registrational study protocols.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, manufacturing dependencies, financial sustainability, and intellectual property challenges.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on developing therapies in oncology and obesity [S1].
- The company’s pipeline includes CRB-701, a next-generation antibody drug conjugate (ADC) targeting Nectin-4 on cancer cells, and CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for obesity treatment [S1].
- CRB-701 is licensed from CSPC Megalith Biopharmaceutical Co. Ltd. for development and commercialization in the U.S., Canada, EU, UK, and Australia [S1].
- CRB-701 is in a Phase 1/2 study in the U.S. and Europe for advanced solid tumors expressing Nectin-4, with dose expansion ongoing and a PD-1 combination arm initiated in June 2025 [S1].
- CRB-701 received FDA fast track designation for relapsed or refractory metastatic cervical cancer (Dec 2024) and recurrent/metastatic head and neck squamous cell carcinoma (Sept 2025) [S1].
- CRB-701 is designed with site-specific conjugation and novel linker technology for stable payload delivery and reduced toxicity, with a longer half-life and lower free plasma payload compared to PADCEV® [S1].
- Phase 1/2 Western study data as of Sept 1, 2025, showed unconfirmed objective response rates (ORR) and disease control rates (DCR) across tumor types (HNSCC, cervical cancer, metastatic urothelial cancer) with favorable safety profile and no dose limiting toxicities [S1].
- CRB-913 is an oral small molecule CB1 receptor inverse agonist formulated to limit brain exposure and improve safety/tolerability compared to GLP-1 drugs, targeting unmet needs in obesity treatment [S1].
- Phase 1a SAD/MAD study of CRB-913 completed in Dec 2025 showed no serious adverse events, no GI intolerability, and neuropsychiatric safety; obese cohort showed mean 2.9% placebo-adjusted weight loss by Day 14 [S1].
- A Phase 1b dose-range finding study (CANYON-1) for CRB-913 was initiated in Dec 2025 with 240 subjects over 12 weeks [S1].
- CRB-601, an anti-αvβ8 integrin monoclonal antibody for solid tumors, has been deprioritized with no further patient enrollment planned [S1].
- The company relies on third-party contract manufacturing organizations for drug supply [S1].
- As of September 30, 2026, Corbus had $30.2 million in cash and equivalents, $118.9 million in current assets, $34.9 million in current liabilities, with a current ratio of 3.4 and cash ratio of 2.86 [S2].
- Net loss for the nine months ended September 30, 2026, was $37.8 million with basic and diluted EPS of -$1.81 [S2].
- Recent news highlights include the launch of a Phase 3 cancer trial for CRB-701 and positive Phase 1b obesity study results for CRB-913 showing 5% weight loss [N1][N2].
- Leonardo Viana Nicacio was appointed Chief Medical Officer in July 2026 [N3].
- The company has teased upcoming key clinical readouts for cancer and obesity programs [N4][N6].
- Corbus targets HPV-linked head and neck cancer with CRB-701 studies [N5].
- Guggenheim initiated coverage with a buy recommendation in April 2026 [N7].
- Wall Street analysts have publicly discussed upside potential for Corbus Pharmaceuticals [N8].
Generated 2026-11-11
- S1 | 2026-03-09 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-09 | www.nasdaq.com | Corbus Pharmaceuticals Launches Phase 3 Cancer Trial, Teases More Obesity Drug Data | https://www.nasdaq.com/articles/corbus-pharmaceuticals-launches-phase-3-cancer-trial-teases-more-obesity-drug-data
- N2 | 2026-09-15 | www.nasdaq.com | Corbus CRB-913 Delivers 5% Weight Loss in Phase 1b Obesity Study | https://www.nasdaq.com/articles/corbus-crb-913-delivers-5-weight-loss-phase-1b-obesity-study
- N3 | 2026-07-06 | www.nasdaq.com | Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio As CMO | https://www.nasdaq.com/articles/corbus-pharmaceuticals-appoints-leonardo-viana-nicacio-cmo
- N4 | 2026-06-09 | www.nasdaq.com | Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near | https://www.nasdaq.com/articles/corbus-pharmaceuticals-teases-cancer-obesity-data-key-clinical-readouts-near
- N5 | 2026-06-01 | www.nasdaq.com | Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study | https://www.nasdaq.com/articles/corbus-pharmaceuticals-targets-hpv-linked-head-and-neck-cancer-crb-701-study
- N6 | 2026-05-22 | www.nasdaq.com | Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout | https://www.nasdaq.com/articles/corbus-pharmaceuticals-teases-key-asco-cancer-data-late-summer-obesity-readout
- N7 | 2026-04-30 | www.nasdaq.com | Guggenheim Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Buy Recommendation | https://www.nasdaq.com/articles/guggenheim-initiates-coverage-corbus-pharmaceuticals-holdings-crbp-buy-recommendation
- N8 | 2026-03-11 | www.nasdaq.com | How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% | https://www.nasdaq.com/articles/how-much-upside-left-corbus-pharmaceuticals-crbp-wall-street-analysts-think-31833
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


